Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

45.01 +1.20 (+2.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 951,029
Open 44.05
Bid (Size) 45.15 (2)
Ask (Size) 46.41 (4)
Prev. Close 43.81
Today's Range 43.39 - 46.20
52wk Range 38.85 - 202.73
Shares Outstanding 74,672,427
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Analyst Ratings for Intellia Therapeutics
Over the past 3 months, 8 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading. 
Via Benzinga

Performance

YTD
-62.07%
-62.07%
1 Month
-9.71%
-9.71%
3 Month
-48.54%
-48.54%
6 Month
-60.21%
-60.21%
1 Year
-37.61%
-37.61%

More News

Read More
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Earnings Preview For Intellia Therapeutics
Via Benzinga
4 Analysts Have This to Say About Intellia Therapeutics
Via Benzinga
How To Attend Intellia Therapeutics Q1 2022 Earnings Conference Call
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
Good Entry Point for Biotech Stocks
Via Talk Markets
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials
Via Benzinga
Here's How Much $100 Invested In Intellia Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022
Via Benzinga
63 Biggest Movers From Yesterday
Via Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
80 Biggest Movers From Yesterday
Via Benzinga
Analyst Ratings For Intellia Therapeutics
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Via Benzinga
Intellia Shares Updated Data On Gene Editing Durability In Rare Disease
Via Benzinga
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Via Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.